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Abstract
Background: Bariatric patients showing poor "focus" during treatment more often failed to lose
weight or maintain reduced weight. Evaluation of these patients identified a number having
attention deficit/hyperactivity disorder (ADHD), evidently a potent factor limiting successful weight
control. After searches found no published reports describing comorbid ADHD and obesity, this
report was conceived to begin exploring the prevalence and characteristics of these patients.
Method: Clinical records of 215 patients receiving obesity treatment during 2000 were reviewed.
Data collected and analyzed included age, sex, beginning and ending body mass index (BMI), number
of clinic visits, months of treatment, and diagnostic category (ADHD, some ADHD symptoms, non-
ADHD). DSM-IV criteria were used, except age of onset was modified to <= 12 years.
Results: Whole sample ADHD prevalence was 27.4% (CI:21.1,32.9), but 42.6% (CI: 36.3% to
48.9%) for BMI >= 40. Mean weight loss among obese patients with ADHD (OB+ADHD) was 2.6
BMI (kg/m2) vs. 4.0 for non-ADHD (NAD) (p < 0.002). For BMI >= 40, OB+ADHD had BMI loss
2.9 vs. 7.0 (NAD) (p < 0.004). OB+ADHD had more clinic visits, with a trend  toward longer
treatment duration.
Conclusions:  ADHD was highly prevalent among obese patients and highest in those with
extreme obesity. Comorbid obesity and ADHD symptoms rendered treatment less successful
compared to NAD counterparts. Reasons for the comorbidity are unknown, but may involve brain
dopamine or insulin receptor activity. If replicated in further studies, these findings have important
implications for treatment of severe and extreme obesity.
Background
Recent U.S. national surveys [1] show that in 1999, 18.9%
of Americans were frankly obese, a marked increase from
17.8% in 1998, underscoring the fact that over the last few
decades, an emerging epidemic of obesity has become a
major cause of preventable death [2] and disease [3]. Rec-
ognizing the effects of obesity on the nation's health, gov-
ernments and industry have vigorously pursued the
genetic, metabolic and environmental roots of obesity [4–
7]. Despite the effort, it remains true that little is known
about prevention of obesity and its treatment remains no
less difficult or failure prone than it ever was [8–10].
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Attention Deficit/Hyperactivity Disorder (ADHD) is also
a common disorder, even if its prevalence is not precisely
known. In children, the rate of occurrence has customarily
been given as 3 to 5%, but recent studies show the condi-
tion is present in 15% or more of school age populations
[11,12]. Persistence of ADHD into adulthood has been
shown to occur in 30 to 50% (or more) of childhood cases
[13], depending on the criteria used [14]. It is clear that
adults with a history of ADHD in childhood have greater
difficulty functioning compared to their non-ADHD peers
[15]. One example is the higher rate of substance use dis-
orders in ADHD adults compared to the general popula-
tion [16], such use often viewed as a kind of "self-
medication" of unpleasant emotions [16]. In obesity, sim-
ilar patterns of eating (seeking immediate gratification,
using food to reduce dysphoria) have been observed [17],
though not previously linked to ADHD.
It is established that obesity has serious medical sequelae,
and that both obesity and ADHD have psychiatric comor-
bidities [18–23], but surprisingly, searches found no exist-
ing literature describing comorbid obesity and ADHD
(OB+ADHD). However, one study [24] reported a poten-
tially relevant correlation between symptoms of conduct
disorder (but not depression) during adolescence and
obesity in early adulthood, attributed to common mecha-
nisms underlying "impulsive aggression" and dysregula-
tion of body weight. The role of impulsivity in this
correlation is important, given that impulsive behavior is
common in adolescents with ADHD, pointing to a con-
nection between ADHD and development of obesity, an
idea consistent with our clinical observation that impul-
sive eating behaviors are common in adult and adolescent
OB+ADHD patients.
With persistent effort some bariatric patients have been
able to achieve and maintain a reduced level of body fat.
In the bariatric clinic at Behavioral Medicine Center for
Treatment and Research (BMedCTR) in Portland, Oregon,
among the patients who failed, a subset was observed to
have unusual difficulty adhering to diet and exercise
plans, and as a result lost less fat mass than typically oc-
curs. Diagnostic evaluation showed a substantial fraction
of these patients had Attention Deficit/Hyperactivity Dis-
order (ADHD), a condition that was recognized in our
clinical work as a risk factor for poor treatment outcome.
Fortunately, ADHD patients often responded to pharma-
cological and behavior therapies, with results that includ-
ed improved task persistence, decreased impulsivity and
distractability, and for some, greater success with weight
control efforts.
Cumulative bariatric clinic experience showed OB+AD-
HD was commonly encountered, and a potent contribu-
tor to obesity treatment failure. In this context it became
clear that more information about OB+ADHD was need-
ed and that wider exposure of this comorbidity would be
valuable (and interesting) to clinicians treating obese pa-
tients. Consequently, this report was constructed to begin
exploring the basic characteristics of this heretofore unrec-
ognized population.
Methods
The primary working hypothesis was that the prevalence
of ADHD among obese patients was higher than in the
general adult population. In addition, it was anticipated
that ADHD patients would have less weight loss, fewer
visits and shorter duration of treatment than their non-
ADHD peers. Differences between groups were not ex-
pected to be widely divergent.
The method used to conduct a systematic examination of
clinical data was a retrospective review of medical records
of patients who had been treated for obesity at BMedCTR
during the period, Jan 1, 2000 through Dec 31, 2000, and
enrolled in treatment by Nov 30, 2000. The clinic's sched-
uling database referenced 215 unique individuals who
were active patients during the study period.
Data relevant to demographic and clinical status was col-
lected from medical records including age, sex, body mass
index (BMI) at first and last visits, interval between first
and last visits, number of visits, and diagnosis of ADHD
entered in the record during the course of obesity treat-
ment. This diagnosis was not determined retrospectively,
although the diagnosis was confirmed to be supported by
the written record of behavioral observations. The 215
records were were divided into 3 groups: patients without
ADHD (NAD), those with ADHD symptoms or behaviors,
but not meeting diagnostic criteria for ADHD (ADSx), and
patients with ADHD (AD).
Diagnosis of ADHD was made by the author during the
course of patients' obesity treatment, using semi-struc-
tured interviews over one or more visits. Structure was in
accord with DSM-IV criteria, that is, a patient needed to
have shown, or given substantial history of 6 or more in-
attentive behaviors to be considered as having ADHD. Pa-
tients who had fewer than 6, but at least 3 inattentive
symptoms were classified as having symptoms of ADHD
but not diagnosed as having the disorder. None of the pa-
tients had as many as 6 hyperactive-impulsive symptoms.
(Patients' inattentive and hyperactive/impulsive behav-
iors were not separately tabulated during records review.)
At the time diagnoses had been made, a behavior was not
considered a symptom of ADHD if occurring only in asso-
ciation with obesity treatment, for example, trouble ad-
hering to diet or exercise plans. A significant level of
impairment associated with symptoms was required for
ADHD to be diagnosed. While many of the patients hadBMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/9
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current or past treatment for depression or anxiety, these
conditions were required to be in remission or insuffi-
ciently prominent to obscure or account for ADHD be-
havior or impairment for the diagnosis of ADHD to be
made.
The interview method is termed semi-structured because
in a clinical setting the approach to each patient was nec-
essarily individualized (at least to some degree). Within
this constraint, information was gathered in a reasonably
consistent manner, in that the same pieces of information
were sought from each patient, the same questions asked
of each, even if the order of inquiry varied, that is to say,
the path through the "decision tree" reflected patients' dif-
ferences.
During the period of treatment, and diagnosis, a single ex-
ception to DSM-IV ADHD diagnostic criteria was made re-
garding age of onset (nominally 7 years), for several
reasons. Pragmatically, adult patients were often uncer-
tain about the precise age symptoms began, though often
able to identify a time in early childhood when symptoms
were already occurring, e.g., "in the 2nd or 3rd grade",
making it impossible to be certain if symptoms were
present before age 7. For middle-aged adults, third party
confirmation of early events was seldom available, leaving
the patient's recall as the only data source. Recent studies
have shown that patient memory was consistent enough
with other information to be useful for diagnostic purpos-
es [25]. Patients' reports were likely to be accurate, but
there were often "gaps" in memory of early experience,
not inconsistent with ADHD in general, favoring an infer-
ence that they didn't remember their behavior rather than
not having had the behavior. It was concluded that the
risk of misdiagnosis by modifying the age of onset criteri-
on was much lower than the risks of not diagnosing a con-
dition for which treatment can make a great difference in
life quality. In other words, for this population the risks of
underdiagnosing ADHD were judged to be far more con-
sequential than risks of overdiagnosing the disorder. Ac-
cordingly, during treatment, diagnosis of ADHD was
made when all other DSM-IV criteria were met and symp-
toms were clearly evident by 12 years of age.
A similar point was made by Wender [26], who argued
that availability of low-risk treatments for debilitating
conditions warrants clinicians using less specific criteria to
avoid excluding patients who may benefit. A different ar-
gument was made by Barkley and Biederman [27], that re-
quiring symptoms to have been present by a single,
specific point in early childhood in order to diagnose
ADHD is not rational, that is, ADHD is better conceptual-
ized as a disorder arising in childhood generally.
None of the ADHD group had a level of hyperactivity-im-
pulsivity meeting DSM-IV criteria, therefore all were clas-
sifiable as having Inattentive Type of ADHD.
Data were tested using Unix-based tools including xmstat
and xlispstat. Significance was set at  = 0.05. Analysis of
variance was applied to means of age, starting BMI, differ-
ence between starting and ending BMI, number of visits
and length of treatment. Chi-square test was used to deter-
mine significance of differences among patient groups
and BMI categories. NIH classification [3] of BMI was
used, defining Obesity III (Extreme Obesity) as BMI >=
40, Obesity classes I and II (Obesity) as BMI 30 to 39.9,
and Overweight as BMI 25 to 29.9.
Results
Results are summarized in Table 1. While the patients in
the sample were predominantly female, there was no sig-
nificant difference in age (F = 0.52, df = 2, 212, p = NS) or
gender distribution (chi-square = 2.35, df = 2, p = 0.31)
among patient groups. Mean Starting BMI – Ending BMI
was 3.32 for males, 3.02 for females, but the difference
was not significant (unpaired t-test, t = 1.73, df = 21, 192,
213, p = 0.09).
Subjects were characterized by a variable level of obesity,
divided into one of three obesity classes (overweight:Ov,
moderate to severe obesity:I-II, and extreme obesity:III),
and a range of symptoms (AD, ADSx, or NAD). These clas-
sifications were organized into a 3  3 array which was
suitable for determining prevalence of ADHD in whole
sample and looking at the differences in ADHD preva-
lence among the classes of obesity.
The whole sample of 215 obese patients, partitioned by
ADHD group, contains 59, or 27.4% (95% CI:21.1% to
32.9%) with AD, 72 or 33.5% (CI:27.2% to 39.8%) were
ADSx, and 84 or 39.1% (CI:32.6% to 45.6%) were NAD.
Chi-square test of patient groups (AD, ADSx, NAD) vs.
obesity classes (III, I-II, Ov) showed that differences in the
3  3 table were significant (chi-square = 11.23, df = 4, p
< 0.025). The proportion of patients having ADHD in
obesity class III (Ob-III) was significantly greater than for
Obesity I-II (Ob-I/II) and Ov (chi-square = 9.86, df = 1, p
= 0.002). However, the proportion of AD in the Ov class
did not significantly differ from Ob-I/II and Ob-III (chi-
square = 2.60, df = 1, p = 0.11).
There were 26 patients with ADHD and Ob-III, which is
42.6% (CI:36.3% to 48.9%) of all 61 Ob-III patients in
the sample. Similarly, there were 23 AD with Ob-I/II
(22.8% [CI:14.6% to 31.0%] of 101 Ob-I/II), and 10 AD
in Ov (18.9% [CI:8.4% to 29.4%] of 53 Ov), though the
value for AD/Ov was not statistically distinct from AD in
other obesity classes.BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/9
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Analysis of variance of patients' BMI at the start of treat-
ment showed a significant difference among the group
means (F = 5.86, df = 2,212, p = 0.003), with AD having a
higher BMI (39.2) than ADSx (35.5) and NAD (34.6).
Further analysis with the Fisher multiple comparison test
found AD differed from ADSx and NAD, but ADSx and
NAD were not significantly different (Fisher, AD-ADSx: p
= 0.001, AD-NAD: p = 0.01, ADSx-NAD: p = 0.49).
Body weight loss was calculated as Starting BMI – Ending
BMI. NAD achieved nearly twice the BMI loss as AD and
ADSx, at means of 4.0, 2.6 and 2.3 respectively (F = 6.25,
df = 2,212, p = 0.002). NAD was distinct from AD and
ADSx (Fisher, NAD-AD: p < 0.009, NAD-ADSx: p < .001,
AD-ADSx: p = 0.666). As percent change from Starting
BMI, mean loss was 11.2%, 6.5% and 6.3% respectively (F
= 8.40, df = 2,212, p =< 0.01), with NAD being significant-
ly different from AD and ADSx which did not differ from
each other (Fisher, NAD-AD: p < 0.001, NAD-ADSx: p <
.001, AD-ADSx: p = 0.93).
The subgroup of patients having Obesity III showed a larg-
er difference in mean BMI change, that is, BMI loss by
ADHD status for members of this subgroup was: NAD 7.0
(SD 4.0), AD 2.9 (SD 4.5) and ADSx 3.4 (SD 2.8) (F =
6.09, df = 2,58, p = 0.004). The weight loss for NAD was
again different from Obesity III patients who were AD or
ADSx, but AD and ADSx were not significantly different
(Fisher, NAD-AD: p < 0.001, NAD-ADSx: p < 0.01, AD-
ADSx: p < 0.657). The Obesity III AD and NAD were ana-
lyzed by the non-parametric approximate randomization
test (AR test) which also showed a significant difference
between the two groups (p = 0.003 (CI:0.0019 to 0.0041),
10000 randomizations).
Among the whole sample of obese patients, mean
number of visits was greater in AD (F = 3.69, df = 2,212, p
= 0.027) with AD differing significantly from NAD and
ADSx (Fisher, AD-NAD: p = 0.02, AD-ADSx: p = 0.01,
NAD-ADSx: p = 0.73). AR test applied to the number of
visits of AD and NAD revealed a marginally significant dif-
ference (p = 0.040 (CI:0.036 to 0.048), 4000 randomiza-
tions). The number of months in treatment was not
significantly different among the patient groups (F = 2.03,
df = 2,212, p = 0.13), though there appeared to be a trend
toward alonger duration of treatment in AD. AR test re-
sults for AD vs. NAD showed a nearly significant differ-
ence, remaining better described as trend toward a
difference (p = 0.054 (CI:0.050 to 0.058), 12000 rand-
omizations).
Discussion
The most important results are the prevalence of ADHD of
27.4% in the sample, and the surprisingly strong associa-
tion between ADHD and Obesity III. Nearly half, 42.6%,
of patients with Obesity III had ADHD, that is, the
OB+ADHD population was concentrated in the obesity
class having the highest mortality and morbidity risks,
and greatest need for effective treatment.
Table 1: 
Age (years) Sex (N) Obesity Class (N) Visits (N)
Group N Mean SD M F III I-II Ov Mean SD
AD 59 44.6 11.4 9 50 26 23 10 56.6 56.6
ADSx 72 42.7 11.0 6 66 18 38 16 37.0 31.9
NAD 84 43.2 10.7 7 77 17 40 27 39.4 44.2
All 215 43.4 10.9 22 193 61 101 53 43.3 45.1
Starting BMI Ending BMI BMI Change Months (N)
Group Mean SD Mean SD Mean SD Mean SD
AD 39.2 10.0 36.6 9.8 2.6 3.5 38.7 33.0
ADSx 35.5 7.1 33.2 6.3 2.3 2.8 30.3 31.4
NAD 34.6 7.1 30.6 6.9 4.0 3.4 28.6 29.0
All 36.2 8.2 33.1 8.0 3.1 3.4 31.0 31.1
Group: AD = diagnosed with ADHD; ADSx = behaviors consistent with ADHD criteria, but insufficient to allow diagnosis; NAD = few or no symp-
toms consistent with ADHD. Obesity class: III (Extreme Obesity) = BMI >= 40; I-II (Obesity) = BMI 30 to 39.9; Ov (Overweight) = BMI < 30. BMI 
Change: Ending BMI – Starting BMI. Months: Total number of months between first and last visits, inclusive.BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/9
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Moreover, at all levels of obesity patients with ADHD
symptoms were less successful at losing weight than non-
ADHD peers. Compared to NAD, AD had a significantly
higher starting BMI (39.6 vs. 34.2), yet lost less weight
(2.6 vs. 4.0 kg/m2). Greater contrast is found in Obesity
III, with NAD in that class achieving more than twice the
weight loss of AD (7.0 vs. 2.9 kg/m2), while mean weight
loss for ADSx did not differ significantly from AD (2.3 vs.
2.6 kg/m2), implying that the presence of even "sub-
threshhold" ADHD symptoms reduces the effectiveness of
obesity treatment. In other words, in OB+ADHD, treat-
ment outcome has stronger association with symptoms of
ADHD than level of obesity. Effect size of ADHD for the
whole sample was only about 0.2, but in Obesity III pa-
tients, effect size was about 0.5, comparable, for example,
to the moderate effect size of SSRI drugs on panic symp-
toms [28].
Impersistence was not the cause of worse results for AD,
who attended more visits than NAD (56.0 vs. 39.4 mean
total visits), over a longer span of time. ADSx was no more
successful than AD, but had fewer visits, comparable to
NAD, in this respect, ADSx showing characteristics inter-
mediate between AD and NAD. The result is AD, ADSx
and NAD having similar rates of clinic visits (AD had 1.5
visits/month, ADSx 1.2 and NAD 1.4), while NAD had the
highest rate of BMI decrease (NAD lost 0.14 BMI/month,
ADSx 0.075 and AD 0.067). However, these statistics have
limited utility, given the large variance in number of visits
and months of treatment. The "slow" aspect of task per-
formance in ADHD has been previously reported [29],
and could be described as a kind of "inefficiency", that is,
taking more time to accomplish less.
The reasons for a strong association between ADHD and
obesity (particularly extreme obesity) are unknown, but
there are a number of reported findings that appear to be
relevant and certainly interesting. For one, evidence exists
that variations of dopamine receptor (DR) genes affect
both conditions. In obesity, DRD2 and DRD4 [30,31]
genes, and in ADHD, the DRD4 [32,33] gene, have been
implicated in the transmission of, or predisposition to,
the disorders, raising the possibility that similar, overlap-
ping or shared DR functioning (or dysfunction) in these
disorders is related to their co-co-occurrence.
DRD2 and a range of dopamine and other genes have
been associated with a "reward deficiency syndrome" [34]
in which insufficient dopamine-mediated "natural" re-
ward leads to use of "unnatural" rewards, such as sub-
stances, gambling, risk taking and inappropriate eating.
This syndrome is associated with obesity [34], and com-
mon in ADHD [22]. The DRD4 gene has been associated
with "novelty seeking" traits, said to be greater in sub-
stance abusers [30], and individuals with both DRD2 and
DRD4 genetic variations may be especially prone to mul-
tiple difficulties (e.g., having both ADHD and "reward de-
ficiency syndrome") [30], further suggesting obesity and
ADHD could share neurobiological attributes.
A recent study showed the availability of striatal DRD2 re-
ceptors was decreased as a function of increasing BMI
[35], supporting the idea that reward-seeking behavior
plays a role in the onset or continuation of obesity. In oth-
er studies, administration of D2 agonists resulted in de-
creases in hyperinsulinemia associated with obesity [36],
and it is known that the brain is richly supplied with insu-
lin receptors, including the cortex and striatal areas [37],
suggesting an intriguing link between insulin resistance,
characteristic of obesity, and dopamine-mediated psychi-
atric symptoms, including ADHD. No doubt, this hypoth-
esis and many far more refined hypotheses will be studied
in coming years and will elucidate the complex neuro-
physiological connections hinted at by the above.
The 27.4% prevalence of ADHD in obese patients is con-
siderably higher than found in the general adult popula-
tion, reported as 4.7% by Murphy and Barkley [38].
Across studies of other specific populations, prevalence of
ADHD or ADHD symptoms was also greater than in gen-
eral, for example, cocaine abusers 12% [39], anxiety disor-
ders 16% [40], panic disorder 22% [41], and substance
abusers 25% [42]. Considering the differing methods and
populations, the reported prevalences are difficult to com-
pare, yet are fairly consistent with one another for the
most part. The prevalence of OB+ADHD in this report is
plausibly within the range of these studies.
The uniformity of the Inattentive subtype of ADHD in this
adult population was not unusual or unexpected, consid-
ering the well-known attenuation of hyperactive and im-
pulsive symptoms observed as children with ADHD grow
into adolescence and adulthood, compared to the much
stronger retention of inattentive symptoms [14]. This is
not to say that ADHD adults don't behave impulsively,
simply that with maturation, continuing hyperactive/im-
pulsive (H/I) behaviors are usually expressed in less obvi-
ous ways than among their school-age counterparts. That
is, while ADHD adults frequently have impairing H/I
symptoms, the number and types of these behaviors sel-
dom meet DSM-IV diagnostic criteria for the H/I or Com-
bined subtype of ADHD. DSM-IV ADHD subtyping,
strictly applied, is likely to have limited correlation to
neurobiological processes (assuming processes reflect im-
pulsivity or disinhibition), since the level of symptomatic
behavior required for diagnosing DSM-IV H/I or Com-
bined subtypes is higher than nearly all ADHD adults will
display, even if substantial H/I behavior is evident.BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/9
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Another factor is that girls, compared to boys, have lower
rates of H/I symptoms, which is associated with lower
likelihood of being diagnosed in childhood, but if diag-
nosed, girls more frequently have the Inattentive subtype
[12]. It would be expected that this difference would per-
sist into adulthood, augmenting the likelihood that Inat-
tentive symptoms would predominate the clinical
presentation. In a sample in which most patients are fe-
male and middle-aged, predominance of the Inattentive
subtype is predictable.
Inevitably, there are numerous caveats and limitations
that apply to this preliminary work. For one, results reflect
the origin of data in clinical practice – hardly ideal from a
research perspective. Treatment settings may favor a high-
er case-finding rate because of the opportunity to observe
and assess behavior is greater than the methods of pro-
spective research designs. For example, ADHD research in-
struments have a sensitivity of 70–90% [43,44], and
would likely identify fewer cases of ADHD than the "gold
standard" of careful clinical assessment, expected to find
most cases. For this report, diagnosis had been made pri-
marily by one interviewer, which could favor consistency,
but also leads to potential biases that skew results. In ad-
dition, the modification of age of onset criterion for
ADHD may increase difficulty of comparing present re-
sults to those of studies using the unmodified criterion.
Clearly, for the purpose of comparing prevalence among
diverse populations, a prospective design is strongly ad-
vantageous, but likely not congruent with the goals of
clinical practice.
Bias could also be introduced by patient factors, such as
comorbid conditions producing symptoms which might
not be easily separable from those found in ADHD, and
erroneously diagnosed as ADHD. Several disorders com-
mon in obese patients fit into this category, e.g., obstruc-
tive sleep apnea, depression, and anxiety disorders. While
the differential characteristics of these conditions, e.g., rel-
ative duration, pervasiveness and continuity of symptoms
can help distinguish one from another, the nature and in-
teractions of these comorbidities are not particularly well-
delineated. While careful clinical practice requires effort to
avoid diagnosing ADHD if symptoms are not sufficiently
distinct from those of confounding disorders, reducing er-
ror requires further research into the effects of comorbidi-
ties intercurrent with ADHD.
Another form of bias originates in patients' predisposition
to endorse symptoms because of dysphoria, negative af-
fectivity, or readiness to attribute distress to some pre-
ferred, rather than actual, source when queried by the
interviewer. For the OB+ADHD population, the idea is
that some patients may have had a preference for endors-
ing ADHD symptoms, instead of accepting more accurate
explanations for distress or lack of obesity treatment
progress, e.g., failure to lose weight while being unwilling
to exercise. ("I can't lose weight because I just get so dis-
tracted.")
Some forms of endorsement bias are readily seen in med-
ical practice, for example, patients who would rather talk
about somatic events than discuss their anxieties or de-
pressed mood. Implications for the OB+ADHD popula-
tion are hard to assess, since this form of bias and its
effects on research of ADHD prevalence have not received
comparable study, nor are there reports of the frequency
of encountering this bias in clinical work with adult
ADHD patients. Moreover, no special measures were tak-
en to reduce or account for such biases during the course
of diagnosing patients in the present sample, rendering it
quite difficult to estimate how much and what kind of ef-
fect biases have had on the above reported prevalences of
OB+ADHD. At this point, it remains an open question,
suggesting additional reasons for cautious interpretation
of the results given in this report.
The demographic characteristics of the sample population
are worth a few comments. Notably, about 90% of the pa-
tients were women, which obviously does not reflect the
general population, but may not be surprising in this con-
text because more women than men are concerned about
weight gain, and are more likely to seek medical care than
male contemporaries. The patients as a group were also
distinctly middle-aged, no doubt reflecting the fact that
older individuals are more likely to be able to afford non-
insured medical care (obesity treatment isn't covered un-
der most policies), and the time to devote to their own
needs.
Some effects of demographic factors on diagnosis of
ADHD were discussed above. Gender and age differences
(e.g., younger patients or higher male to female ratio)
could conceivably affect the range and intesity of ADHD
symptoms that are observed, prevalence findings, and in-
dividual as well as aggregate response to obesity treat-
ment.
In addition, generalizability of conclusions based on the
data in this report are limited by a modest sample size,
and uncertainty that the bariatric patients in the sample
were truly representative of the general obese population.
Results could be misleading, for example, if the sample
had a disproportion of individuals with serious medical
or psychiatric problems, higher weight or greater social
skill deficits, even if the sample is construed to be typical
of those seen in similar practices.BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/9
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Conclusion
This report is explicitly exploratory, and its findings need
to be replicated in larger and more systematic studies.
Nonetheless, these findings are already quite interesting
and could have implications for the understanding of the
etiology of obesity as well as the treatment of obesity. The
nature of the connections, to the extent that they exist, be-
tween attention and obesity is of course not at all clear,
but the results may point to forms of attentional compo-
nents and impulsivity playing a role in the onset or con-
tinuation of obesity, or that attentional mechanisms are
linked in some way to metabolic and energy storage regu-
lation.
Implications for clinical practice may be of more immedi-
ate consequence. Treatment of obesity has been marginal-
ly effective at best, particularly for extreme obesity. If an
attentional disorder is present, conceivably its treatment
could improve obesity treatment outcome, which makes
awareness of the ADHD-obesity comorbidity pragmatical-
ly important. It has been shown that reduction of body
weight as small as 5% substantially reduces the morbidity
and mortality risks of obesity, so even if recognizing and
treating ADHD is only a modest contributor to reducing
body fat mass, it is worthwhile on that grounds alone.
Moreover, the impairment of ADHD is an intrinsic reason
to diagnose and treat the condition, because even if co-
morbid obesity were not changed, normalizing brain
function in ADHD sufferers more often than not provides
substantial benefit and improved quality of life.
The apparent association of OB+ADHD, relatively poor
obesity treatment outcome and high prevalence of
OB+ADHD (27.4%), especially in the extremely obese
(42.6%), argue that comorbid ADHD increases the health
risks of obesity, and that extreme obesity, itself a stressful
condition, adds burden to the profound impairments
common in ADHD. The chance that more knowledge
could lead to reduction of suffering, disability and eco-
nomic cost offers compelling reasons for further investiga-
tion of this subject. Inclusion of more diverse and non-
clinical populations of obese and extremely obese indi-
viduals, and using research designs that better account for
rater and subject biases, inter-rater reliability, and diag-
nostic methodology, will likely give more definitive an-
swers to this report's questions and implications.
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